Robert F. Kelley
Robert F. Kelley
Verified email at
Cited by
Cited by
IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding
SG Hymowitz, EH Filvaroff, JP Yin, J Lee, L Cai, P Risser, M Maruoka, ...
The EMBO journal, 2001
Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies
K Newton, ML Matsumoto, IE Wertz, DS Kirkpatrick, JR Lill, J Tan, ...
Cell 134 (4), 668-678, 2008
High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment
P Carter, RF Kelley, ML Rodrigues, B Snedecor, M Covarrubias, ...
Bio/technology 10 (2), 163-167, 1992
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5
SG Hymowitz, HW Christinger, G Fuh, M Ultsch, M O'Connell, RF Kelley, ...
Molecular cell 4 (4), 563-571, 1999
K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody
ML Matsumoto, KE Wickliffe, KC Dong, C Yu, I Bosanac, D Bustos, L Phu, ...
Molecular cell 39 (3), 477-484, 2010
Tween protects recombinant human growth hormone against agitation‐induced damage via hydrophobic interactions
NB Bam, JL Cleland, J Yang, MC Manning, JF Carpenter, RF Kelley, ...
Journal of pharmaceutical sciences 87 (12), 1554-1559, 1998
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL
SG Hymowitz, MP O'Connell, MH Ultsch, A Hurst, K Totpal, A Ashkenazi, ...
Biochemistry 39 (4), 633-640, 2000
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than …
RF Kelley, K Totpal, SH Lindstrom, M Mathieu, K Billeci, L DeForge, R Pai, ...
Journal of Biological Chemistry 280 (3), 2205-2212, 2005
Tissue factor: an enzyme cofactor and a true receptor
JH Morrissey
Thrombosis and haemostasis 86 (07), 66-74, 2001
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer
TT Junttila, K Parsons, C Olsson, Y Lu, Y Xin, J Theriault, L Crocker, ...
Cancer research 70 (11), 4481-4489, 2010
FAB Assembly and Enrichment in a Monovalent Phage Display System
LJ Garrard, M Yang, MP O'Connell, RF Kelley, DJ Henner
Bio/technology 9 (12), 1373-1377, 1991
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding
SG Hymowitz, DR Patel, HJA Wallweber, S Runyon, M Yan, JP Yin, ...
Journal of Biological Chemistry 280 (8), 7218-7227, 2005
A strategy for risk mitigation of antibodies with fast clearance
I Hötzel, FP Theil, LJ Bernstein, S Prabhu, R Deng, L Quintana, J Lutman, ...
MAbs 4 (6), 753-760, 2012
Thermodynamic analysis of an antibody functional epitope
RF Kelley, MP O'Connell
Biochemistry 32 (27), 6828-6835, 1993
In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff, S Pai, E Hilario, B Zhang, C Li, ...
Proceedings of the National Academy of Sciences 111 (52), 18601-18606, 2014
Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule
ME Bromberg, R Sundaram, RJ Homer, A Garen, WH Konigsberg
Thrombosis and haemostasis 82 (07), 88-92, 1999
Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site
YA Muller, MH Ultsch, RF Kelley, AM de Vos
Biochemistry 33 (36), 10864-10870, 1994
Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab
M Ultsch, J Bevers, G Nakamura, R Vandlen, RF Kelley, LC Wu, ...
Journal of molecular biology 425 (8), 1330-1339, 2013
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells
TT Junttila, J Li, J Johnston, M Hristopoulos, R Clark, D Ellerman, ...
Cancer research 74 (19), 5561-5571, 2014
Anti-CD3 antibodies and methods of use
X Chen, MS Dennis, AJ Ebens Jr, RF Kelley, MA Mathieu
US Patent 10,174,124, 2019
The system can't perform the operation now. Try again later.
Articles 1–20